Compare Abeona Therapeutics Inc (ABEO) vs VF Corp (VFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs VF Corp — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while VF Corp trades at $15.99 (market cap $6.45B). The key difference: VF Corp is far larger — about 17.3× Abeona Therapeutics Inc's market cap, and VF Corp pays a 2.19% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | VFC | |
|---|---|---|
Market Cap | $373.32M | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $21.55 |
52-Week Low | $4.17 | $11.66 |
Enterprise Value | $228.22M | $10.60B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VFC trades at $16.45, up 0.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings showed a Q1 2026 miss after two prior beats, while revenue declined to $9.50B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M. Analyst consensus is mixed with a $20.00 price target, and news highlights focus on turnaround progress and debt reduction.
VFC's outlook hinges on executing its brand turnaround, particularly at Vans, with guided revenue growth for 2027 offering potential upside. Risks include weak consumer confidence and high leverage, though deleveraging efforts are underway. The stock presents a value opportunity with a low P/S of 0.68, but investors face near-term volatility from earnings uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
